Neil L. Berinstein, M.D.
Ontario Institute for Cancer Research
Neil L. Berinstein, M.D., has recently joined the Ontario Institute for Cancer Research as director of translation research and is helping to develop novel oncolytic virus and cancer vaccine approaches for the treatment of cancer. Previously, he was chief scientific officer at IRX Therapeutics and led the pre-clinical and clinical research program around the IRX2 immunomodulator. He was assistant vice president and global program leader at Sanofi Pasteur, where he was in charge of leading the development of Sanofi's cancer vaccines, both strategically and operationally. Dr. Berinstein was responsible for interacting with international collaborators and leading researchers who were collaborating with Sanofi Pasteur, either at pre-clinical or clinical levels. He saw to completion several multicenter phase I and phase II studies in Canada and the U.S. in colorectal and melanoma projects. He is a scientific advisor for several cancer biotechnology companies including Immunovaccine, Biovest, and Spectrum.
Dr. Berinstein currently holds multiple academic and professional positions, including professor in the department of medicine at the University of Toronto, and as an active staff member at the Odette Cancer Center of the Sunnybrook Health Science Center. He was the vice president of the Cancer Vaccine Consortium, sponsored by the Sabin Vaccine Institute, and more recently, is part of the executive steering committee of the Cancer Research Institute (CRI)-sponsored Cancer Immunotherapy Consortium. He was also formerly a member and leader of the scientific review committee of the Leukemia Research Fund.
Dr. Berinstein is the recipient of numerous grants in his research career and has published six book chapters, and over 100 peer-reviewed, invited, or review papers to date. He received his pre-medical degree and Medical Doctorate from University of Manitoba and further specialty and research training at the University of Toronto and Stanford University.